Bukwang Pharmaceutical Co., Ltd. (KRX:003000)
3,765.00
-105.00 (-2.71%)
At close: Nov 21, 2025
Bukwang Pharmaceutical Revenue
Bukwang Pharmaceutical had revenue of 47.81B KRW in the quarter ending September 30, 2025, with 12.25% growth. This brings the company's revenue in the last twelve months to 184.38B, up 32.72% year-over-year. In the year 2024, Bukwang Pharmaceutical had annual revenue of 160.09B with 27.13% growth.
Revenue (ttm)
184.38B
Revenue Growth
+32.72%
P/S Ratio
2.11
Revenue / Employee
299.81M
Employees
615
Market Cap
389.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 160.09B | 34.16B | 27.13% |
| Dec 31, 2023 | 125.93B | -64.98B | -34.04% |
| Dec 31, 2022 | 190.91B | 8.42B | 4.61% |
| Dec 31, 2021 | 182.49B | 12.83B | 7.56% |
| Dec 31, 2020 | 169.66B | 1.47B | 0.87% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 148.28B |